Davola Maria Eugenia, Mossman Karen Louise
Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, Michael DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
Oncoimmunology. 2019 Mar 28;8(6):e1581528. doi: 10.1080/2162402X.2019.1596006. eCollection 2019.
Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considered an essential aspect of oncolytic virotherapy. To improve oncolytic virotherapy, many studies focus on increasing virus replication and spread. In this article, we open for discussion the traditional dogma that correlates replication with the efficacy of OVs, pointing out several examples that oppose this principle.
溶瘤病毒（OVs）通过多模式作用机制优先靶向并杀死癌细胞，而不影响健康细胞。虽然从历史上看，OVs的直接杀伤活性被认为是主要作用模式，但现在启动或增强宿主抗肿瘤免疫反应被视为溶瘤病毒疗法的一个重要方面。为了改进溶瘤病毒疗法，许多研究专注于增加病毒的复制和传播。在本文中，我们开启讨论与OVs疗效相关的传统教条，指出了几个与此原则相悖的例子。
